Hi @Galilee13 and fellow Share Holders,I sent Dr G some...

Hi @Galilee13 and fellow Share Holders,

I sent Dr G some questions for a response during the EGM tomorrow. Good luck everyone, hopefully this bounce might give us a leg up for the future.


Hi Dr Yacov,

I sent an email to you a couple of weeks ago with a collection of questions from your loyal shareholders at Hot Copper, however you quite rightly replyed saying that your time was precious and that I should resend the questions and you would provide answers during the upcoming EGM.

These questions are in no particular order:

1. As you previously advised me that the Emergency NMPA Approval Documentation had been filed in China, could you please advise when the application was submitted and has or do you intend to submit an Emergency Approval application in the USA for the FDA. Please provide an update to the Emergency Approval Applications (EAA),

2. Update on the UK Division,

3. Update on the FDA in USA for the Patch & Prizma Jacket,

4. Update on the Uk division - do we still have a functioning UK division with staff, premises, remote monitoring facility etc? And what is the status of the 10 x UK hospital trials from the July 2019 announcement? Have any of these trials converted to a sale, or are they all now lost opportunities?

Is the chinese manufacturing plant actually producing any product right now? If not, how long will it take to ramp up these facilities - once GMV receive some significant orders? Last time we heard GMV were still compiling all the hospital test results for the Chinese NMPA certification, and these test results would be submitted around end of April 2020 from memory?,

5. Update on the Taiwan deal scheduled for April,

6. Update on the HKZE listing,

7. Can they announce the Clinical Trials results to the market? The company mentioned lucrative Medicare programs in the US last year and then touched on it in the preliminary report. Can they share more details?.

8. What steps is the company taking to improve reporting? For example, meeting minimum reporting requirements and submitting on time, not copying data from other companies etc,

9. What is the status of the 10 x UK hospital trials from the July 2019 announcement? Have any of these trials converted to a sale, or are they all now lost opportunities?

10. I have been emailing Yacov, Brendan and of late Henry a long list of similar questions for over 2 years now. Basically I haven't received an answer to any questions. So, we can continue to send emails and hope Dr Yacov will provide an update. Or as I said to Yacov in my last email. If you continue to ignore shareholders you can expect these type of questions from the floor at the upcoming company presentation. So, IMO the only way we will get some answers is we need shareholders to attend the JP Equity conference and ask.

Thankyou in advance,

Rubes